LIVIVO - Search results -

Search results

Result 1 - 10 of total 286

Search options

Article ; Online: Multiple sclerosis diagnostic criteria: From poser to the 2017 revised McDonald criteria.

de Seze, Jérôme / Bigaut, Kévin

Presse medicale (Paris, France : 1983)

2021 Volume 50, Issue 2, Page(s) 104089

MeSH term(s)	Disease Progression ; Humans ; Magnetic Resonance Imaging ; Multiple Sclerosis/diagnosis ; Retrospective Studies
Language	English
Publishing date	2021-10-28
Publishing country	France
Document type	Journal Article
ZDB-ID	120943-7
ISSN	2213-0276 ; 0032-7867 ; 0755-4982 ; 0301-1518
ISSN (online)	2213-0276
ISSN	0032-7867 ; 0755-4982 ; 0301-1518
DOI	10.1016/j.lpm.2021.104089
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 794: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.87: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

de Seze, Jerome

Current opinion in neurology

2018 Volume 32, Issue 1, Page(s) 111–114

Abstract: Purpose of review: Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disease of the central nervous system, particularly characterized by disabling episodes of optic neuritis and longitudinally extensive transverse myelitis. The ... ...

Abstract	Purpose of review: Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disease of the central nervous system, particularly characterized by disabling episodes of optic neuritis and longitudinally extensive transverse myelitis. The pathogenic characteristic is the presence of antiaquaporin 4 antibodies (AQP4-Abs) in the cerebrospinal fluid and serum of most of the affected patients. However, a proportion of the patients (around 20-30%) that have a typical phenotype of NMO are seronegative for AQP4-Abs. Recent findings: A proportion of these seronegative patients (20%) can express antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs). The presence of MOG-Abs in the sera of seronegative NMO patients is associated with typical features of NMO in several patients but in some of them with relapsing episodes of optic neuritis or transverse myelitis. Summary: In this article, we review the clinical and therapeutic aspects of MOG-Ab-positive NMOSD, with a specific focus on optic neuritis.
MeSH term(s)	Aquaporin 4/immunology ; Autoantibodies/immunology ; Humans ; Myelin-Oligodendrocyte Glycoprotein/immunology ; Neuromyelitis Optica/immunology
Chemical Substances	Aquaporin 4 ; Autoantibodies ; Myelin-Oligodendrocyte Glycoprotein
Language	English
Publishing date	2018-10-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1182686-1
ISSN	1473-6551 ; 1350-7540
ISSN (online)	1473-6551
ISSN	1350-7540
DOI	10.1097/WCO.0000000000000650
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2524: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review.

Pinto, Ashwin A / De Seze, Jerome / Jacob, Anu / Reddel, Stephen / Yudina, Anna / Tan, Kevin

Therapeutic advances in neurological disorders

2023 Volume 16, Page(s) 17562864231154306

Abstract: Background: Intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (TPE) are among the main immunotherapies for neurological disorders. Their benefit is greatest in immune-mediated conditions, but their distinct efficacy cannot be simply ... ...

Abstract	Background: Intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (TPE) are among the main immunotherapies for neurological disorders. Their benefit is greatest in immune-mediated conditions, but their distinct efficacy cannot be simply explained. Objectives: This review aimed to systematically identify studies comparing the efficacy of TPE and IVIg treatments for selected autoimmune neurological disorders and identify optimal therapies for each condition. Data sources and methods: PubMed, MEDLINE and Embase databases were searched for original publications from 1990 to 2021. Additional publications were identified Results: Forty-four studies were included on Guillain-Barré syndrome (20 studies - 12 adult, 5 paediatric, 3 all ages), myasthenia gravis (11 studies -8 adult, 3 paediatric), chronic immune-mediated polyradiculoneuropathy (3 studies -1 adult, 2 paediatric), encephalitis (1 study in adults), neuromyelitis optica spectrum disorders (5 studies -2 adult, 3 all ages) and other conditions (4 studies - all ages). TPE and IVIg were mostly similarly efficacious, measured by clinical outcomes and disease severity scores. Some studies recommended IVIg as easy to administer. TPE procedures, however, have been simplified and the safety has been improved. TPE is currently recommended for management of neuromyelitis optica spectrum disorder relapses and some myasthenia gravis subtypes, in which rapid removal of autoantibodies is crucial. Conclusion: Despite some limitations (e.g. the low evidence levels), this review provides an extensive 30-year-long overview of treatments for various conditions. Both IVIg and TPE are usually comparably efficacious options for autoimmune neurological disorders, with few exceptions. Treatment choices should be patient-tailored and based on available clinical resources. Better designed studies are needed to provide higher-level quality of evidence regarding clinical efficacy of TPE and IVIg treatments.
Language	English
Publishing date	2023-03-29
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2442245-9
ISSN	1756-2864 ; 1756-2856
ISSN (online)	1756-2864
ISSN	1756-2856
DOI	10.1177/17562864231154306
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?

de Seze, Jérome

Brain : a journal of neurology

2017 Volume 140, Issue 12, Page(s) 3072–3075

MeSH term(s)	Aquaporin 4 ; Humans ; Myelin-Oligodendrocyte Glycoprotein ; Neuromyelitis Optica ; Prognosis ; United Kingdom
Chemical Substances	Aquaporin 4 ; Myelin-Oligodendrocyte Glycoprotein
Language	English
Publishing date	2017-11-29
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	80072-7
ISSN	1460-2156 ; 0006-8950
ISSN (online)	1460-2156
ISSN	0006-8950
DOI	10.1093/brain/awx292
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.26: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study.

Marignier, Romain / Laplaud, David / Zéphir, Hélène / Papeix, Caroline / Leray, Emmanuelle / Amri, Ekbel / Piotaix, Mickaël / de Sèze, Jérôme

Frontiers in neurology

2024 Volume 14, Page(s) 1303874

Abstract: Background: Eculizumab, a humanized monoclonal antibody targeting the C5 complement protein, has been approved for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). ...

Abstract	Background: Eculizumab, a humanized monoclonal antibody targeting the C5 complement protein, has been approved for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). The aim of this study is to evaluate the long-term effectiveness and safety of eculizumab in French adults with NMOSD and to describe patients' characteristics, disability, and quality of life using data collected in a real-world setting. Methods: This is the protocol for ECUP4, an ongoing prospective, observational, non-comparative, multicenter study conducted in 32 reference centers in France. Eligible patients must also be enrolled in NOMADMUS, a nested cohort of the French national multiple sclerosis registry (OFSEP). The primary endpoint is the annualized relapse rate. Secondary endpoints include the long-term safety of eculizumab, as well as patients' characteristics, treatment outcomes, disability, pain, visual acuity, and quality of life. Visits and treatments follow routine clinical practice. The case report forms (CRF) comprise data recorded in the context of the NOMADMUS cohort, collected during routine visits. The inclusion period is planned for 3 years, with no limitation on the number of patients enrolled. The maximum follow-up duration will be 5.5 years. Conclusion: The efficacy and safety of eculizumab in patients with AQP4+ NMOSD have been demonstrated in randomized clinical trials that showed a significant reduction in the risk of relapse, with a safety profile consistent with other indications. This study will provide clinical and patient-reported evidence of the benefits of eculizumab, using data from a real-world setting in France. Trial registration number: This study is registered at the French public repertory Health data Hub, N° F20211228123801. All information can be accessed at: https://www.health-data-hub.fr/.
Language	English
Publishing date	2024-01-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2564214-5
ISSN	1664-2295
ISSN	1664-2295
DOI	10.3389/fneur.2023.1303874
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis.

de Seze, Jerome / Dive, Dominique / Ayrignac, Xavier / Castelnovo, Giovanni / Payet, Marianne / Rayah, Amel / Gobbi, Claudio / Vermersch, Patrick / Zecca, Chiara

Neurology and therapy

2024

Abstract: The number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisations and ... ...

Abstract	The number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisations and malignancy. Aging people with MS have higher rates of comorbidities versus aged-matched controls, increasing the individual risk of disability. We review the therapeutic properties of cladribine tablets (CladT) in ageing people with RMS, with regard to their utility for allowing these individuals to cease continuous administration of a DMT (i.e. to act as an "exit therapy"). CladT is thought to be an immune reconstitution therapy, in that two short courses of oral treatment 1 year apart provide suppression of MS disease activity in responders that far outlasts the duration of treatment and post-treatment reductions in lymphocyte counts. Post hoc analyses, long-term follow-up of populations with RMS in randomised trials, and real-world evidence suggest that the efficacy of CladT is probably independent of age, although more data in the elderly are still needed. No clear adverse signals for lymphopenia or other adverse safety signals have emerged with increasing age, although immunosenescence in the setting of age-related "inflammaging" may predispose elderly patients to a higher risk of infections. Updating vaccination status is recommended, especially against pneumococci and herpes zoster for older patients, to minimise the risk of these infections. CladT may be a useful alternative treatment for ageing people with MS who often bear a burden of multiple comorbidities and polypharmacy and who are more exposed to the adverse effects of continuous immunosuppressive therapy.
Language	English
Publishing date	2024-04-08
Publishing country	New Zealand
Document type	Journal Article ; Review
ISSN	2193-8253
ISSN	2193-8253
DOI	10.1007/s40120-024-00603-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.

de Seze, Jérôme / Clerc, Christine / Béreau, Matthieu / Bourre, Bertrand / Zephir, Hélène / Collongues, Nicolas / Kremer, Laurent / Vermersch, Patrick / Bigaut, Kevin

Multiple sclerosis journal - experimental, translational and clinical

2024 Volume 10, Issue 1, Page(s) 20552173241233952

Abstract: Objective: To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.: Methods: We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy ... ...

Abstract	Objective: To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder. Methods: We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests. Results: The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds ( Conclusion: Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.
Language	English
Publishing date	2024-02-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	2841884-0
ISSN	2055-2173 ; 2055-2173
ISSN (online)	2055-2173
ISSN	2055-2173
DOI	10.1177/20552173241233952
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.

Ciron, Jonathan / Bourre, Bertrand / Castelnovo, Giovanni / Guennoc, Anne Marie / De Sèze, Jérôme / Ben-Amor, Ali Frederic / Savarin, Carine / Vermersch, Patrick

Neurology and therapy

2024

Abstract: Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune reconstitution ... ...

Abstract	Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune reconstitution therapy. In contrast to most high-efficacy DMTs, which act via continuous immunosuppression, two short courses of oral treatment with CladT at the beginning of years 1 and 2 of treatment provide long-term control of MS disease activity in responders to treatment, without the need for any further pharmacological treatment for several years. Although the labelling for CladT does not provide guidance beyond the initial treatment courses, real-world data on the therapeutic use of CladT from registries of previous clinical trial participants and patients treated in routine practice indicate that MS disease activity is controlled for a period of years beyond this time for a substantial proportion of patients. Moreover, this clinical experience has provided useful information on how to initiate and manage treatment with CladT. In this article we, a group of expert neurologists from France, provide recommendations on the initiation of CladT in DMT-naïve patients, how to switch from existing DMTs to CladT for patients with continuing MS disease activity, how to manage patients during the first 2 years of treatment and finally, how to manage patients with or without MS disease activity in years 3, 4 and beyond after initiating treatment with CladT. We believe that optimisation of the use of CladT beyond its initial courses of treatment will maximise the benefits of this treatment, especially early in the course of MS when suppression of focal inflammation in the CNS is a clinical priority to limit MS disease progression.
Language	English
Publishing date	2024-03-15
Publishing country	New Zealand
Document type	Journal Article ; Review
ISSN	2193-8253
ISSN	2193-8253
DOI	10.1007/s40120-024-00589-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.

Einsiedler, Maximilian / Kremer, Laurent / Fleury, Marie / Collongues, Nicolas / De Sèze, Jérôme / Bigaut, Kévin

Journal of neurology

2022 Volume 269, Issue 9, Page(s) 4846–4852

Abstract: Background: Anti-CD20 monoclonal antibodies are recently introduced treatments in progressive MS and real-world data are lacking.: Objective: The aim of this study is to describe a cohort of progressive MS patients treated with ocrelizumab or ... ...

Abstract	Background: Anti-CD20 monoclonal antibodies are recently introduced treatments in progressive MS and real-world data are lacking. Objective: The aim of this study is to describe a cohort of progressive MS patients treated with ocrelizumab or rituximab in a real-world setting. Methods: This monocentric prospective cohort study at the University Hospital of Strasbourg included patients with primary progressive or secondary progressive MS that started treatment with anti-CD20 antibodies before June 2019. Every six months, patients were assessed using the following standardized clinical evaluations: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9-HPT) and Symbol Digit Modalities Test (SDMT). The primary analysis considered EDSS progression (of at least 1.0 if EDSS ≤ 5.5 and at least 0.5 if EDSS ≥ 6.0). Results: We included 108 patients, with a median age upon inclusion of 53 years [48.0-58.0]. 72% were classified as primary progressive forms. Median baseline EDSS was 6.0 [4.0-6.5]. EDSS was significantly correlated with T25FW, SDMT and 9-HPT. Following 2 years of treatment, 38.9% of patients presented EDSS progression compared to baseline. Conclusion: Our large cohort confirms tolerance of these treatments in a real-world setting. Standardized clinical assessments could improve detection of deteriorating patients. Further studies are needed to establish predictive factors.
MeSH term(s)	Antigens, CD20 ; Disability Evaluation ; Disease Progression ; Follow-Up Studies ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy ; Middle Aged ; Multiple Sclerosis ; Multiple Sclerosis, Chronic Progressive/diagnosis ; Multiple Sclerosis, Chronic Progressive/drug therapy ; Prospective Studies
Chemical Substances	Antigens, CD20 ; Immunologic Factors
Language	English
Publishing date	2022-04-17
Publishing country	Germany
Document type	Journal Article
ZDB-ID	187050-6
ISSN	1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
ISSN (online)	1432-1459
ISSN	0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
DOI	10.1007/s00415-022-11124-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui II Zs.40: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.

Clavelou, Pierre / Castelnovo, Giovanni / Pourcher, Valérie / De Sèze, Jerome / Vermersch, Patrick / Ben-Amor, Ali-Frederic / Savarin, Carine / Defer, Gilles

Neurology and therapy

2023 Volume 12, Issue 5, Page(s) 1457–1476

Abstract: Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been ... ...

Abstract	Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonged period in most patients, without need for continued DMT. Each course of CladT induces a profound reduction in B lymphocytes that recovers over months, and serious lymphopenia (Grade 3-4) is uncommon. Smaller reductions in levels of T lymphocytes occur slightly later: on average, these remain within the normal range and repopulate progressively. A larger effect occurs on CD8 vs. CD4 cells. Reactivation of latent or opportunistic infections (e.g. varicella zoster, tuberculosis) is mostly associated with very low lymphocyte counts (< 200/mm
Language	English
Publishing date	2023-06-29
Publishing country	New Zealand
Document type	Journal Article ; Review
ISSN	2193-8253
ISSN	2193-8253
DOI	10.1007/s40120-023-00496-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED